CNX-774,99.46%
产品编号:Bellancom-13943| CAS NO:1202759-32-7| 分子式:C26H22FN7O3| 分子量:499.50
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
CNX-774
| 产品介绍 | CNX-774 是具有口服活性的、不可逆的、选择性的 BTK 抑制剂,其 IC50 小于 1 nM。CNX-774 特异性靶向 Btk 的 Cys 481进行共价修饰。 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 生物活性 | CNX-774 is an orally active, irreversible and selective BTK inhibitor, with an IC50 of < 1 nM. CNX-774 specifically targets Cysteine 481 of Btk for covalent modification.  | ||||||||||||||||
| 体外研究 |                                         
                                        
                                             CNX-774 strongly inhibits Btk activity in Ramos cells with an IC50 of 1-10 nM. CNX-774 demonstrates strong time- and dose-dependent occupancy of Btk in Ramos cells. 西域 has not independently confirmed the accuracy of these methods. They are for reference only.  | ||||||||||||||||
| 体内研究 |                                         
                                        
                                             CNX-774 is stable and non-reactive in fresh human and rat whole blood and does not covalently bond to any of the mid-level abundance human plasma proteins. 西域 has not independently confirmed the accuracy of these methods. They are for reference only.  | ||||||||||||||||
| 体内研究 |                                         
                                        
                                             CNX-774 is stable and non-reactive in fresh human and rat whole blood and does not covalently bond to any of the mid-level abundance human plasma proteins. 西域 has not independently confirmed the accuracy of these methods. They are for reference only.  | ||||||||||||||||
| 性状 | Solid | ||||||||||||||||
| 溶解性数据 | 
                                        
                                             In Vitro:  
                                            DMSO : ≥ 45 mg/mL (90.09 mM) * "≥" means soluble, but saturation unknown. 配制储备液 
                                                
 
 
                                                    *
                                                     
                                            
                                        
                                        
                                            请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 
                                            请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: 
                                                    ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
                                                        以下溶剂前显示的百 
  | ||||||||||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere.  | ||||||||||||||||
| 储存方式 | 
                                
  | ||||||||||||||||
| 参考文献 | 
                            
                                    
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                        
 
 
 
 
浙公网安备 33010802013016号